150 related articles for article (PubMed ID: 33994145)
1. Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.
Tran DT; Vo VK; Le MT; Chuang L; Nguyen VQH
Gynecol Oncol; 2021 Jul; 162(1):113-119. PubMed ID: 33994145
[TBL] [Abstract][Full Text] [Related]
2. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
Karlsen MA; Høgdall EV; Christensen IJ; Borgfeldt C; Kalapotharakos G; Zdrazilova-Dubska L; Chovanec J; Lok CA; Stiekema A; Mutz-Dehbalaie I; Rosenthal AN; Moore EK; Schodin BA; Sumpaico WW; Sundfeldt K; Kristjansdottir B; Zapardiel I; Høgdall CK
Gynecol Oncol; 2015 Sep; 138(3):640-6. PubMed ID: 26086566
[TBL] [Abstract][Full Text] [Related]
3. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Wang Z; Tao X; Ying C
Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors.
Minar L; Felsinger M; Cermakova Z; Zlamal F; Bienertova-Vasku J
Int J Gynaecol Obstet; 2018 Feb; 140(2):241-246. PubMed ID: 29086914
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
6. Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?
Yoshida A; Derchain SF; Pitta DR; Andrade LA; Sarian LO
Gynecol Oncol; 2016 Mar; 140(3):481-5. PubMed ID: 26825617
[TBL] [Abstract][Full Text] [Related]
7. Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam.
Huy NVQ; Van Khoa V; Tam LM; Vinh TQ; Tung NS; Thanh CN; Chuang L
Gynecol Oncol Rep; 2018 Aug; 25():110-114. PubMed ID: 30109256
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of CA125, HE4, ROMA, and CPH-I in identifying primary ovarian cancer.
Luo HJ; Hu ZD; Cui M; Zhang XF; Tian WY; Ma CQ; Ren YN; Dong ZL
J Obstet Gynaecol Res; 2023 Mar; 49(3):998-1006. PubMed ID: 36609691
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
10. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
11. Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms.
Song Z; Wang X; Fu J; Wang P; Chen X; Zhang D
Front Surg; 2022; 9():1068492. PubMed ID: 36713666
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the risk of ovarian malignancy algorithm and Copenhagen Index for the preoperative assessment of Japanese women with ovarian tumors.
Iizuka M; Hamada Y; Matsushima J; Ichikawa T; Irie T; Yamaguchi N; Sakamoto S; Ban S; Takakura S
J Obstet Gynaecol Res; 2023 Nov; 49(11):2717-2727. PubMed ID: 37643727
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
14. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
Špacir Prskalo Z; Bulić P; Langer S; Gaće M; Puljiz M; Danolić D; Alvir I; Mamić I; Šušnjar L; Mayer L
J Obstet Gynaecol; 2019 Feb; 39(2):195-201. PubMed ID: 30207507
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
16. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
Lycke M; Kristjansdottir B; Sundfeldt K
Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
[TBL] [Abstract][Full Text] [Related]
17. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
19. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.
Pitta Dda R; Sarian LO; Barreta A; Campos EA; Andrade LL; Fachini AM; Campbell LM; Derchain S
BMC Cancer; 2013 Sep; 13():423. PubMed ID: 24044637
[TBL] [Abstract][Full Text] [Related]
20. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
